Xilio shares rose 8% after reporting positive early data for cancer drug XTX301, which showed two partial responses and was well tolerated. The company began dosing patients in Phase 2 and secured a $17.5 million milestone payment from Gilead, extending its cash runway into 2027. Retail investors say the $38 million market cap undervalues its $140 million cash and partnerships.